BAM Logo

Urine Oxalate and Citrate

EPTIS factsheet 142599 | Last revision 2024-05-22 | URL: https://www.eptis.bam.de/pts142599 https://www.eptis.bam.de/pts142599

PT provider
PT provider Weqas Weqas
Based in United Kingdom
Remarks The amounts of oxalate and citrate excreted in urine and their urinary concentrations are important risk factors for the development of kidney stones. Citrate in the urine has long been recognized as an inhibitor of calcium salt crystallization and patients having low citrate levels (hypocitraturia) are at increased risk of kidney stone formation. There are several metabolic disorders associated with low urinary citrate concentrations, any condition which lowers renal tubular pH or intracellular pH, may decrease citrate, e.g. metabolic acidosis, increased acid ingestion, hypokalaemia or hypomagnesaemia. This programme is designed to span both the analytical and clinically relevant range for the diagnosis and management of hyperoxaluria and hypocitraturia. The samples consist of challenging samples at low concentration for citrate as well as a panel of 6 linearly related pools produced from urine donations spiked with oxalate and citrate to span the analytical range. Each sample is distributed on 6 occasions with a minimum of 36 samples distributed over the year. The programme assesses both laboratory and method performance, including linearity, bias, within and between batch imprecision. Key Features: - Liquid human serum samples require no pre-analytical preparation. - Samples cover both analytical and clinically relevant range. - Challenging samples at low citrate concentration. - Linearly related panel assists with your compliance to ISO 15189. For more information: https://www.weqas.com/services/eqa/oxalate-citrate/ or contact@weqas.com
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Filtered and acidified human urine Oxalate Routine testing methods (recommended)
Citrate Routine testing methods (recommended)
Aims of the PT scheme
Target group of participants The programme assesses both laboratory and method performance, including linearity, bias, within and between batch imprecision.
Linked to specific legislation / standards Accreditation by UKAS on the basis of ISO/IEC 17025, 17043 and 15195
Additional, subsidiary aims validation of testing methods
Number of participants
Accredited or otherwise reviewed by a 3rd party

Accredited by UKAS on the basis of ISO/IEC 17043

Operation is commissioned / requested by
Fees and frequency
Participation fee https://www.weqas.com/participantzone/subscription-charges/
Regularly operated Yes (Frequency: Monthly. Samples: 3 x 2.5mL.)
Year of first operation 2003
Contact details of the PT provider
Provider Contact person
Unit 6, Parc Ty Glas
CF14 5DU Cardiff
United Kingdom

Phone: 44 (0) 2920 314750
Web: http://www.weqas.com http://www.weqas.com
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884
Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5